Treatment of<unk>  is centered on treating the underlying condition. Transfusions of platelets or fresh frozen plasma can be considered in cases of significant bleeding, or those with a planned invasive procedure. The target goal of such transfusion depends on the clinical situation. Cryoprecipitate can be considered in those with a low fibrinogen level. Treatment of thrombosis with anticoagulants such as heparin is rarely used due to the risk of bleeding. Recombinant human activated protein C was previously recommended in those with severe sepsis and<unk> , but drotrecogin alfa has been shown to confer no benefit and was withdrawn from the market in 2011. Recombinant factor VII has been proposed as a "last resort" in those with severe hemorrhage due to obstetric or other causes, but conclusions about its use are still insufficient.
Disseminated intravascular coagulation
Thrombotic thrombocytopenic purpura
Heparin-induced thrombocytopenia
Hemolytic–uremic syndrome
Venom-induced consumption coagulopathy
Sticky platelet syndrome
Gray platelet syndrome
Pseudo gray platelet syndrome